These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 20309789)

  • 41. Removal of branched-chain amino acids and alpha-ketoisocaproate by haemofiltration and haemodiafiltration.
    Gouyon JB; Semama D; Prévot A; Desgres J
    J Inherit Metab Dis; 1996; 19(5):610-20. PubMed ID: 8892016
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cerebral edema in maple syrup urine disease.
    Lungarotti MS; Calabro A; Signorini E; Garibaldi LR
    Am J Dis Child; 1982 Jul; 136(7):648. PubMed ID: 7091101
    [No Abstract]   [Full Text] [Related]  

  • 43. Nasogastric drip feeding as the only treatment of neonatal maple syrup urine disease.
    Parini R; Sereni LP; Bagozzi DC; Corbetta C; Rabier D; Narcy C; Hubert P; Saudubray JM
    Pediatrics; 1993 Aug; 92(2):280-3. PubMed ID: 8337030
    [No Abstract]   [Full Text] [Related]  

  • 44. An early diagnosis leads to a good prognosis: a patient with maple syrup urine disease--screened by tandem mass spectrometry.
    Lin JF; Chiu PC; Hsu HY; Lin SM; Chen YY; Hsieh KS
    Acta Paediatr Taiwan; 2004; 45(5):287-9. PubMed ID: 15868812
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Continuous venovenous haemofiltration in the acute treatment of inborn errors of metabolism.
    Jouvet P; Poggi F; Saudubray JM
    Pediatr Nephrol; 1995 Feb; 9(1):127. PubMed ID: 7742213
    [No Abstract]   [Full Text] [Related]  

  • 46. Total branched-chain amino acids requirement in patients with maple syrup urine disease by use of indicator amino acid oxidation with L-[1-13C]phenylalanine.
    Riazi R; Rafii M; Clarke JT; Wykes LJ; Ball RO; Pencharz PB
    Am J Physiol Endocrinol Metab; 2004 Jul; 287(1):E142-9. PubMed ID: 14970005
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Computed tomography in maple syrup urine disease.
    Taccone A; Schiaffino MC; Cerone R; Fondelli MP; Romano C
    Eur J Radiol; 1992; 14(3):207-12. PubMed ID: 1563430
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clearance of toxic metabolites during therapy for inborn errors of metabolism.
    Ring E; Zobel G; Stöckler S
    J Pediatr; 1990 Aug; 117(2 Pt 1):349-50. PubMed ID: 2380843
    [No Abstract]   [Full Text] [Related]  

  • 49. Characteristics of continuous venovenous hemodiafiltration in the acute treatment of inherited metabolic disorders.
    Eminoğlu FT; Öncül Ü; Kahveci F; Okulu E; Kraja E; Köse E; Kendirli T
    Pediatr Nephrol; 2022 Jun; 37(6):1387-1397. PubMed ID: 34693482
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Metabolic disorders of branched-chain amino acids: most common forms of organic aciduria in the neonatal period].
    Sperl W; Lehnert W
    Klin Padiatr; 1990; 202(5):334-9. PubMed ID: 2214593
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Continuous Venovenous Hemodiafiltration in the Treatment of Maple Syrup Urine Disease.
    Demirkol D; Şık G; Topal N; Çıtak A; Zeybek Ç; Tüten A; Bilge I
    Blood Purif; 2016; 42(1):27-32. PubMed ID: 26998605
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The intermediate form of maple syrup disease].
    Rittinger O; Bachmann C; Irnberger T; Pilz P; Walter GF; Wendel U; Plöchl E
    Klin Padiatr; 1986; 198(1):37-43. PubMed ID: 3959487
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dysmyelination in the brain of adolescents and young adults with maple syrup urine disease.
    Schönberger S; Schweiger B; Schwahn B; Schwarz M; Wendel U
    Mol Genet Metab; 2004 May; 82(1):69-75. PubMed ID: 15110325
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tailoring of the diet for the individual in maple syrup urine disease: long-term home dietary treatment of an adult patient with MSUD by monitoring of daily intake with a personal computer. A case report.
    Lie IE; Haugstad S; Holm H
    Hum Nutr Appl Nutr; 1985 Apr; 39(2):130-6. PubMed ID: 3839494
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Duration of extracorporeal therapy in acute maple syrup urine disease: a kinetic model.
    Phan V; Clermont MJ; Merouani A; Litalien C; Tucci M; Lambert M; Mitchell G; Jouvet P
    Pediatr Nephrol; 2006 May; 21(5):698-704. PubMed ID: 16518628
    [TBL] [Abstract][Full Text] [Related]  

  • 56. DNA damage in an animal model of maple syrup urine disease.
    Scaini G; Jeremias IC; Morais MO; Borges GD; Munhoz BP; Leffa DD; Andrade VM; Schuck PF; Ferreira GC; Streck EL
    Mol Genet Metab; 2012 Jun; 106(2):169-74. PubMed ID: 22560665
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Maple syrup urine disease: findings on CT and MR scans of the brain in 10 infants.
    Brismar J; Aqeel A; Brismar G; Coates R; Gascon G; Ozand P
    AJNR Am J Neuroradiol; 1990; 11(6):1219-28. PubMed ID: 2124065
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intermittent maple syrup urine disease: two case reports.
    Axler O; Holmquist P
    Pediatrics; 2014 Feb; 133(2):e458-60. PubMed ID: 24394677
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A case of classical maple syrup urine disease that was successfully managed by living donor liver transplantation.
    Takano C; Ishige M; Ogawa E; Usui H; Kagawa R; Tajima G; Fujiki R; Fukao T; Mizuta K; Fuchigami T; Takahashi S
    Pediatr Transplant; 2017 Aug; 21(5):. PubMed ID: 28612395
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Diagnosis of MSUD by newborn screening allows early intervention without extraneous detoxification.
    Heldt K; Schwahn B; Marquardt I; Grotzke M; Wendel U
    Mol Genet Metab; 2005 Apr; 84(4):313-6. PubMed ID: 15781191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.